Study on the Anticancer Activity of Coumarin Derivatives by Molecular Modeling

Chemical Biology and Drug Design

Volumn 78, Issue 4, 2011, Pages 651-658

  Huang, Xiao Y ^a   Shan, Zhi J ^a   Zhai, Hong L ^a   Su, Li ^a   Zhang, Xiao Y ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Anticancer activity; CoMFA; CoMSIA; Coumarin; Docking; Protein kinase 2

Indexed keywords

CASEIN KINASE II; COUMARIN DERIVATIVE; HYDROXYL GROUP; LYSINE; LYSINE 68; UNCLASSIFIED DRUG; WATER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG BINDING; ENZYME INHIBITION; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; STATIC ELECTRICITY;

ANTINEOPLASTIC AGENTS; CASEIN KINASE II; COUMARINS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

RUMEX;

EID: 80052609836     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01195.x     Document Type: Article

References (26)

1. Meggio F., Pinna L. (2003) One-thousand-and-one substrates of protein kinase CK2. FASEB J;17:349-368.
2. Litchfield D. (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J;369:1-15.
3. ' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J Biol Chem;273:21291-21297.
4. Clark M., Cramer R. III, Van Opdenbosch N. (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem;10:982-1012.
5. Seeber S., Issinger O., Holm T., Kristensen L., Guerra B. (2005) Validation of protein kinase CK2 as oncological target. Apoptosis;10:875-885.
6. Tawfic S., Yu S., Wang H., Faust R., Davis A., Ahmed K. (2001) Protein kinase CK2 signal in neoplasia. Histol Histopathol;16:573-582.
7. Chilin A., Battistutta R., Bortolato A., Cozza G., Zanatta S., Poletto G. et al. (2008) Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: An integrate approach to elucidate the putative binding motif and explain structurëCactivity relationships. J Med Chem;51:752-759.
8. Lacy A., O'Kennedy R. (2004) Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des;10:3797-3811.
9. Zhang N., Zhong R. (2010) Docking and 3D-QSAR studies of 7-hydroxycoumarin derivatives as CK2 inhibitors. Eur J Med Chem;45:292-297.
10. Richard D. III, David E., Jeffrey D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:5959-5967.
11. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem;37:4130-4146.
12. Zhang Z., An L., Hu W., Xiang Y. (2007) 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach. J Comput Aided Mol Des;21:145-153.
13. Avery M., Muraleedharan K., Desai P., Bandyopadhyaya A., Furtado M., Tekwani B. (2003) Structure-activity relationships of the antimalarial agent artemisinin. 8. design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. J Med Chem;46:4244-4258.
14. Associates T. (1999) Sybyl Molecular Modeling Software Packages. Missouri: Tripos Inc.
15. Gasteiger J., Marsili M. (1980) Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. Tetrahedron;36:3219-3228.
16. Bohm M., Sturzebecher J., Klebe G. (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem;42:458-477.
17. Kowalski B. (1984) Chemometrics, Mathematics and Statistics in Chemistry. Dordrecht, The Netherlands: Springer.
18. Ståhle L., Wold S. (1987) Partial least squares analysis with cross-validation for the two-class problem: a Monte Carlo study. J Chemometr;1:185-196.
19. Wold S., Ruhe A., Wold H., Dunn W. III (1984) The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput;5:735-743.
20. Cramer R. III, Bunce J., Patterson D., Frank I. (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. QSAR;7:18-25.
21. Wold S. (1978) Cross-validatory estimation of the number of components in factor and principal components models. Technometrics;20:397-405.
22. Morris G., Goodsell D., Halliday R., Huey R., Hart W., Belew R. et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem;19:1639-1662.
23. Hu Z., Wang S., Southerland W. (2004) Dock Odysseys II. ACS Division of Chemical Information Final Program. The 228th ACS national meeting, Philadelphia, PA, USA.
24. De Moliner E., Moro S., Sarno S., Zagotto G., Zanotti G., Pinna L. et al. (2003) Inhibition of protein kinase CK2 by anthraquinone-related compounds. J Biol Chem;278:1831-1836.
25. Donnelly A., Mays J., Burlison J., Nelson J., Vielhauer G., Holzbeierlein J. et al. (2008) The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J Org Chem;73:8901-8920.
26. Burlison J., Avila C., Vielhauer G., Lubbers D., Holzbeierlein J., Blagg B. (2008) Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J Org Chem;73:2130-2137.